A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies
PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
312
Participants
Timeline
Start Date
December 29, 2021
Primary Completion Date
June 20, 2026
Study Completion Date
September 20, 2026
Conditions
Acute Myeloid LeukemiaLymphomaMultiple Myeloma
Interventions
DRUG
SYHX1903
SYHX1903 tablets, orally, qd
All Listed Sponsors
lead
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
INDUSTRY
NCT05055791 - A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies | Biotech Hunter | Biotech Hunter